Eli Lilly | LLY - Operating Profit


Eli Lilly reported $9.78B in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Abbott USD 2.13B 281M Jun/2026
ALKERMES USD -65.93M 17.65M Jun/2026
Amgen USD 4.61B 777M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Baxter International USD 276M 210M Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Drreddys Laboratories INR 829M 13.5B Mar/2026
Eli Lilly USD 9.78B 792M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Glaxosmithkline GBP 2.29B 3.08M Mar/2026
J&J USD 7.48B 860M Jun/2026
Medtronic USD 2.09B 354M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Novartis USD 4.75B 515M Jun/2026
Novartis USD 4.24B 171M Mar/2026
Novo Nordisk DKK 59.62B 27.24B Mar/2026
Perrigo USD 33.6M 50.8M Mar/2026
Pfizer USD 667M 4.32B Jun/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 75.49M 7M Mar/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 2.38B 449M Jun/2026
Sanofi EUR 2.27B 771M Mar/2026
United Therapeutics USD 325.8M 340.4M Mar/2026
Zoetis USD 865M 30M Mar/2026